JSIBD–Pfizer Quality Improvement Grants for IBD Care (Japan)

Deadline: 30-Mar-2026

The Japanese Society for Inflammatory Bowel Disease (JSIBD) and Pfizer have launched a Quality Improvement Grant Program to enhance medical care for IBD patients in Japan. The program provides up to 2 million Japanese Yen per project over a two-year period (June 2026–May 2028), supporting initiatives that improve clinical practice, professional education, and healthcare networks in the field of inflammatory bowel disease.

Overview of the Grant Program

The Quality Improvement (QI) Grant Program is a collaborative initiative by the Japanese Society for Inflammatory Bowel Disease (JSIBD) and Pfizer. It aims to support healthcare-focused projects that:

• Strengthen appropriate medical care for patients with IBD

• Establish systems supporting best clinical practices

• Improve the skills of healthcare professionals through education and structured initiatives

• Build and reinforce professional networks within the IBD community

This competitive program is intended to accelerate improvements in clinical practice and education in the management of inflammatory bowel disease across Japan.

Key Objectives

The QI Grant Program focuses on:

1. Quality Improvement Initiatives

   • Enhancing the delivery of appropriate and consistent care for IBD patients

   • Implementing best practices in clinical settings

2. Professional Education and Training

   • Developing programs to strengthen the knowledge and skills of healthcare professionals

   • Supporting workshops, seminars, and educational resources

3. Network Development

   • Facilitating collaboration between healthcare providers

   • Encouraging sustainable professional communities in IBD care

Who Is Eligible?

Eligible applicants include:

• Medical, dental, nursing, allied health, and pharmacy professional schools

• Hospitals and healthcare institutions of various sizes

• Professional organizations and societies

• Government agencies and public health entities

• Other entities with a healthcare improvement mission

Not Eligible: Individual applicants, independent medical practice groups, or entities outside the healthcare improvement domain.

Funding Details

• Maximum Grant Amount: 2,000,000 Japanese Yen per project

• Project Duration: Up to 2 years (June 1, 2026 – May 31, 2028)

• Funding supports structured QI activities that enhance clinical care, professional education, and network development

Why This Grant Matters

The grant is designed to:

• Improve the quality and consistency of IBD care in Japan

• Support the professional development of healthcare workers in gastroenterology

• Establish sustainable networks for knowledge sharing and collaboration

• Promote systematic improvements in patient outcomes through QI methodologies

By funding projects with measurable impact, the program contributes to advancing national standards for IBD treatment.

How to Apply / Program Process

1. Confirm Eligibility – Only organizations aligned with healthcare improvement can apply.

2. Develop a Project Proposal – Outline the QI initiative, objectives, methodology, expected outcomes, and timelines.

3. Define Project Duration and Budget – Ensure the proposal does not exceed 2 million Yen and fits within the two-year period.

4. Submit Application – Follow JSIBD and Pfizer guidelines for competitive review submission.

5. Expert Review – Applications are evaluated by a panel of experts based on potential impact, feasibility, and alignment with program objectives.

6. Project Implementation – Selected projects implement QI activities, track progress, and report outcomes to JSIBD.

Tips for a Strong Application

• Clearly define quality improvement goals and measurable outcomes

• Show how the project strengthens healthcare professional skills

• Emphasize collaboration and network-building efforts

• Provide a realistic timeline and detailed budget

• Highlight potential sustainability beyond the project period

Common Mistakes to Avoid

• Applying as an individual or independent practice group

• Submitting proposals with unclear objectives or measurable outcomes

• Exceeding the maximum funding limit or project duration

• Ignoring professional collaboration and network-building components

Frequently Asked Questions (FAQs)

1. Who can apply for the grant?

Eligible applicants are healthcare-related organizations such as professional schools, hospitals, professional societies, and government agencies.

2. What is the maximum funding available?

Up to 2 million Japanese Yen per project.

3. How long can projects last?

Projects can run for a maximum of two years, from June 1, 2026, to May 31, 2028.

4. Are individual healthcare professionals eligible?

No. Individual applicants and independent medical practice groups are not eligible.

5. What types of projects are supported?

Projects that strengthen IBD care delivery, enhance professional education, and build collaborative healthcare networks.

6. How are applications evaluated?

An expert review panel assesses proposals based on potential impact, feasibility, and alignment with program goals.

7. Is project sustainability considered?

Yes. Projects demonstrating long-term benefits and network-building are highly encouraged.

Conclusion

The JSIBD and Pfizer Quality Improvement Grant Program provides a strategic opportunity for healthcare organizations in Japan to improve IBD patient care. By funding structured initiatives that enhance clinical practice, professional education, and collaboration, the program fosters systematic, sustainable improvements in the management of inflammatory bowel disease across the country.

For more information, visit Pfizer.